Par Will Pay Santarus $100 Million to Settle Patent Litigation Over Generic Heartburn Rx

Par Pharmaceutical Cos. and Santarus Inc. have settled patent litigation over Par’s sales of a generic version of the heartburn treatment Zegerid, with Par paying $100 million to Santarus to close out the infringement case (Santarus, Inc. v. Par Pharmaceutical, Inc.settlement announced).

In a Sept. 22 8-K filing with the Securities and Exchange Commission, Par said it would pay $100 million to the plaintiffs in the case, which, in addition to Santarus, include Salix Pharmaceuticals Inc. and the Curators of the University of Missouri.

Under the settlement, the patent infringement lawsuit will be dismissed with prejudice, and Par ...